RX-3117: Phase Ib data

Data from 41 patients with solid tumors in the Phase Ib portion of an open-label, dose-escalation, U.S. Phase Ib/IIa trial showed that oral RX-3117 given 3, 5 or 7 times per week for the first 3 weeks...